1. Is Human Enhancement also a Personal Matter?Vincent Menuz, Thierry Hurlimann & Béatrice Godard - 2013 - Science and Engineering Ethics 19 (1):161-177.
    Emerging technologies are increasingly used in an attempt to “enhance the human body and/or mind” beyond the contemporary standards that characterize human beings. Yet, such standards are deeply controversial and it is not an easy task to determine whether the application of a given technology to an individual and its outcome can be defined as a human enhancement or not. Despite much debate on its potential or actual ethical and social impacts, human enhancement is not subject to any consensual definition. (...)
    Direct download (5 more)  
    Export citation  
    Bookmark   4 citations  
  2.  24
    The elusive ideal of inclusiveness: lessons from a worldwide survey of neurologists on the ethical issues raised by whole-genome sequencing.Thierry Hurlimann, Iris Jaitovich Groisman & Béatrice Godard - 2017 - BMC Medical Ethics 18 (1):28.
    The anticipation of ethical issues that may arise with the clinical use of genomic technologies is crucial to envision their future implementation in a manner sensitive to local contexts. Yet, populations in low- and middle-income countries are underrepresented in studies that aim to explore stakeholders’ perspectives on the use of such technologies. Within the framework of a research project entitled “Personalized medicine in the treatment of epilepsy”, we sought to increase inclusiveness by widening the reach of our survey, inviting neurologists (...)
    Direct download (7 more)  
    Export citation  
    Bookmark   1 citation  
  3.  17
    Exploring neurologists’ perspectives on the return of next generation sequencing results to their patients: a needed step in the development of guidelines.Thierry Hurlimann, Iris Jaitovich Groisman & Béatrice Godard - 2018 - BMC Medical Ethics 19 (1):81.
    The use of Next Generation Sequencing such as Whole Genome Sequencing is a promising step towards a better understanding and treatment of neurological diseases. WGS can result into unexpected information, and information with uncertain clinical significance. In the context of a Genome Canada project on ‘Personalized Medicine in the Treatment of Epilepsy’, we intended to address these challenges surveying neurologists’ opinions about the type of results that should be returned, and their professional responsibility toward recontacting patients regarding new discovered mutations. (...)
    Direct download (4 more)  
    Export citation